PLUS vs SPSC

The company presents a stark dichotomy between strong growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 2/9. While the stock is attractively valued with a PEG ratio of 0.82 and trades well below its growth-based intrinsic value of $165.2, the deterministic health markers and bearish technical trend suggest underlying instability. Strong revenue and earnings growth are currently offsetting these risks, but the low F-Score indicates a need for caution regarding cash flow or operational efficiency.

SPSC exhibits exceptional fundamental health with a Piotroski F-Score of 8/9 and negligible debt (Debt/Equity 0.01), providing a strong safety floor. While the stock is trading below its intrinsic value ($72.57) and analyst target ($78.82), it is plagued by severe negative price momentum and bearish insider activity. The company's legendary track record of beating earnings estimates for 25 consecutive quarters suggests operational excellence, but the market is currently discounting the stock heavily. The disconnect between rock-solid fundamentals and a collapsing share price warrants a neutral stance until a technical bottom is established.